KR101773506B1 - Ｍｕｃ1 항체 - Google Patents

Ｍｕｃ1 항체 Download PDF

Info

Publication number
KR101773506B1
KR101773506B1 KR1020127005121A KR20127005121A KR101773506B1 KR 101773506 B1 KR101773506 B1 KR 101773506B1 KR 1020127005121 A KR1020127005121 A KR 1020127005121A KR 20127005121 A KR20127005121 A KR 20127005121A KR 101773506 B1 KR101773506 B1 KR 101773506B1
Authority
KR
South Korea
Prior art keywords
ser
antibody
val
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127005121A
Other languages
English (en)
Korean (ko)
Other versions
KR20120051724A (ko
Inventor
슈테펜 골렛츠
안트제 다니엘치크
레나트 슈탄
우베 카르스텐
Original Assignee
글리코토페 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글리코토페 게엠베하 filed Critical 글리코토페 게엠베하
Publication of KR20120051724A publication Critical patent/KR20120051724A/ko
Application granted granted Critical
Publication of KR101773506B1 publication Critical patent/KR101773506B1/ko
Assigned to 다이이찌 산쿄 가부시키가이샤 reassignment 다이이찌 산쿄 가부시키가이샤 권리의 전부이전등록 Assignors: 글리코토페 게엠베하
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020127005121A 2009-07-31 2010-07-30 Ｍｕｃ1 항체 Active KR101773506B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23021109P 2009-07-31 2009-07-31
US61/230,211 2009-07-31
EP09009942.5 2009-07-31
EP09009942A EP2281844A1 (en) 2009-07-31 2009-07-31 MUC 1 antibodies
PCT/EP2010/004663 WO2011012309A1 (en) 2009-07-31 2010-07-30 Muc1 antibodies

Publications (2)

Publication Number Publication Date
KR20120051724A KR20120051724A (ko) 2012-05-22
KR101773506B1 true KR101773506B1 (ko) 2017-08-31

Family

ID=41460131

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127005121A Active KR101773506B1 (ko) 2009-07-31 2010-07-30 Ｍｕｃ1 항체

Country Status (17)

Country Link
US (1) US9217038B2 (https=)
EP (3) EP2281844A1 (https=)
JP (2) JP5922018B2 (https=)
KR (1) KR101773506B1 (https=)
CN (1) CN102574926B (https=)
AR (1) AR077334A1 (https=)
AU (1) AU2010278302B2 (https=)
BR (1) BR112012002226A2 (https=)
CA (1) CA2768888C (https=)
CU (1) CU23972B1 (https=)
EA (1) EA029954B1 (https=)
IL (1) IL217827A (https=)
MX (1) MX2012000874A (https=)
NZ (1) NZ597563A (https=)
SG (2) SG10201404019XA (https=)
WO (1) WO2011012309A1 (https=)
ZA (1) ZA201200166B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3539981A1 (en) 2006-09-10 2019-09-18 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
PT2603528T (pt) 2010-08-10 2016-12-01 Glycotope Gmbh Anticorpos glicosilados em fab
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
ES2686313T3 (es) 2011-08-22 2018-10-17 Glycotope Gmbh Microorganismos que portan un antígeno tumoral
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
EP2963126B1 (en) * 2013-03-01 2019-04-03 Saitama Medical University Method for evaluating side-effect onset risk in anticancer drug treatment, including detecting muc4 gene polymorphism
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CA2938819A1 (en) 2014-02-06 2015-08-13 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Antibody to mucin 4 (muc4) glycopeptide and uses thereof
US10239950B2 (en) * 2014-04-28 2019-03-26 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof
WO2016026143A1 (en) * 2014-08-22 2016-02-25 Huiru Wang Saccharide-based biomarkers and therapeutics
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
CN116199790A (zh) 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
WO2017139975A1 (en) 2016-02-19 2017-08-24 Huiru Wang Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
EP3570881A4 (en) * 2017-01-18 2020-08-19 Nanocruise Pharmaceutical Ltd. MONOCLONAL AND HUMANIZED ANTIBODIES DIRECTED AGAINST CANCER GLYCOPEPTIDE
US20190343953A1 (en) 2017-01-27 2019-11-14 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
WO2018178047A1 (en) 2017-03-29 2018-10-04 Glycotope Gmbh Multispecific antibody constructs binding to muc1 and cd3
WO2018178046A1 (en) 2017-03-29 2018-10-04 Glycotope Gmbh Humanized anti-cd40 antibodies
US20200148785A1 (en) * 2017-03-29 2020-05-14 Glycotope (GmbH) Pd-l1 and ta-muc1 antibodies
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
NZ762505A (en) 2017-09-29 2026-03-27 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
US12605469B2 (en) 2017-10-02 2026-04-21 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
US11161911B2 (en) 2017-10-23 2021-11-02 Go Therapeutics, Inc. Anti-glyco-MUC1 antibodies and their uses
BR112020008001A2 (pt) * 2017-10-24 2020-10-20 Go Therapeutics, Inc. anticorpo anti-glico-muc1 ou fragmento de ligação de antígeno, proteína de fusão, receptor de antígeno quimérico, conjugado de anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, composição farmacêutica, e, métodos de tratar câncer e de detectar câncer em uma amostra biológica.
CA3090407A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
CN108982854B (zh) * 2018-06-19 2021-07-27 哈尔滨医科大学 蛋白质muc13在制备诊断肝内胆管癌的试剂中的应用
JP7541930B2 (ja) * 2018-06-29 2024-08-29 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ１抗体およびその使用
SG11202103670XA (en) 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
CN113631229B (zh) 2019-03-25 2025-09-23 第一三共株式会社 抗体－吡咯并苯并二氮杂卓衍生物偶联物
CA3139180A1 (en) 2019-03-27 2020-10-01 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
WO2023121448A1 (en) * 2021-12-21 2023-06-29 Merus N.V. Binding domains against cancer-associated muc1
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
TW202506190A (zh) 2023-04-05 2025-02-16 日商第一三共股份有限公司 利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292643A1 (en) 2003-01-23 2006-12-28 Steffen Goletz Recognition molecules for the treatment and detection of tumours
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
JP3698370B2 (ja) 1992-04-13 2005-09-21 ダナ−ファーバー キャンサー インスティチュート インク 癌腫抗原用抗体
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6465220B1 (en) * 1998-12-21 2002-10-15 Glycozym Aps Glycosylation using GalNac-T4 transferase
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
ATE290879T1 (de) 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
ES2524442T3 (es) 2002-07-22 2014-12-09 Glycotope Gmbh Procedimiento para la producción de una mucina (MUC1) inmunoestimulante
DK1530628T3 (da) 2002-08-16 2011-01-10 Glycotope Gmbh Fremgangsmåde til fremstilling af temperaturinducerede tumorcellelysater til anvendelse som immunogene forbindelser
SI1654353T1 (sl) 2003-08-18 2013-09-30 Glycotope Gmbh Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe
CN103627670B (zh) 2004-02-13 2016-12-21 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292643A1 (en) 2003-01-23 2006-12-28 Steffen Goletz Recognition molecules for the treatment and detection of tumours
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies

Also Published As

Publication number Publication date
AU2010278302B2 (en) 2014-12-18
SG10201404019XA (en) 2014-09-26
CU23972B1 (es) 2013-12-27
WO2011012309A8 (en) 2011-04-07
AR077334A1 (es) 2011-08-17
KR20120051724A (ko) 2012-05-22
ZA201200166B (en) 2013-03-27
JP6272916B2 (ja) 2018-01-31
NZ597563A (en) 2013-08-30
CA2768888A1 (en) 2011-02-03
CN102574926A (zh) 2012-07-11
CN102574926B (zh) 2014-10-15
US9217038B2 (en) 2015-12-22
IL217827A0 (en) 2012-03-29
BR112012002226A2 (pt) 2016-11-08
CU20120019A7 (es) 2012-06-21
AU2010278302A1 (en) 2012-02-09
EA029954B1 (ru) 2018-06-29
US20120128676A1 (en) 2012-05-24
JP5922018B2 (ja) 2016-05-24
SG177527A1 (en) 2012-02-28
EP2281844A1 (en) 2011-02-09
CA2768888C (en) 2019-02-26
MX2012000874A (es) 2012-02-01
EA201270207A1 (ru) 2012-07-30
EP2459595A1 (en) 2012-06-06
WO2011012309A1 (en) 2011-02-03
IL217827A (en) 2017-05-29
JP2013500703A (ja) 2013-01-10
EP3421497A1 (en) 2019-01-02
JP2016041771A (ja) 2016-03-31

Similar Documents

Publication Publication Date Title
KR101773506B1 (ko) Ｍｕｃ1 항체
KR101782487B1 (ko) 신규 항-메소텔린 항체 및 이를 포함하는 조성물
JP5568478B2 (ja) 癌細胞で発現するｃｄ−４３およびｃｅａの炭水化物含有エピトープを認識する抗体およびそれを使用する方法
EP3130607B1 (en) Muc1* antibodies
TW202525859A (zh) 全人源的抗ｂ細胞成熟抗原（ｂｃｍａ）單鏈抗體及其應用
JP2021524740A (ja) 抗ｍｕｃ１抗体
EP3981793A1 (en) Ceacam5-resistant monoclonal antibody and preparation method thereof and use thereof
EP4289862A1 (en) Anti-human b7-h3 antibody and application thereof
JPWO2015053381A1 (ja) 抗ポドプラニン抗体
JP7410051B2 (ja) 細胞内への鉄の取り込み阻害剤
WO2022075439A1 (ja) 抗トランスフェリンレセプター抗体の薬効又は感受性の判定方法
WO2023027164A1 (ja) Ｒｏｓ（活性酸素種）産生増強剤
JP7622926B2 (ja) 癌性腹膜炎の治療薬
JP6847434B2 (ja) 抗ポドプラニン抗体
EP4512423A1 (en) Therapeutic agent for nk cell tumor
EP4703383A1 (en) Prolactin receptor antibody and use thereof
HK40122549A (en) Therapeutic agent for nk cell tumor
HK40068402A (en) Ceacam5-resistant monoclonal antibody and preparation method thereof and use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150730

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161220

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170622

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170825

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170828

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20200818

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210817

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20220817

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20230816

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20240813

Start annual number: 8

End annual number: 8